This protocol covers active chronic lymphocytic leukemia (CLL) in patients whose disease carries unmutated IGHV status, with confirmed absence of TP53 mutation and del(17p), and who are not medically fit due to significant comorbidity.

Clinical Scenario

Active CLL with unmutated IGHV status, without TP53 mutation and without del(17p), in a patient who is not medically fit due to significant comorbidity. This molecular and fitness profile defines the treatment context and narrows the appropriate options.

Treatment Approach

For medically unfit patients in this setting, the approach involves a choice between targeted therapy regimens — including time-limited combination therapy and continuous targeted therapy options — with the preferred choice guided by patient fitness, tolerance, and disease characteristics.

The complete regimen, full option list, sequencing, and evidence levels are in the structured protocol below.

References

CLL with unmutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies):
Unfit patients: venetoclax plus obinutuzumab or ibrutinib or acalabrutinib [I, A] or chlorambucil plus obinutuzumab.
One of the two following treatment options should be chosen [I, A]:
Venetoclax plus rituximab for 24 months;
Ibrutinib or acalabrutinib or other BTKis (if available) as continuous therapy.
The PI3K inhibitor idelalisib in combination with rituximab [II, B];
In case of long-lasting remissions (>3 years) to prior time-limited therapy, patients may be re-exposed to the same treatment regimen, though data are limited with no long-term observation [II, B].

View source ↗

Treatment of Active CLL with Unmutated IGHV Status and Significant Comorbidity (Medically Unfit Patients)